Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30208112 | 1.00 | LMNA (0.73) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL5237489 | 0.95 | LMNA (0.67) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL29660566 | 0.95 | LMNA (0.67) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL13926625 | 0.88 | ALDH1A1 (0.57) | LMNAALDH1A1MAPTGPR119ENPP2 | |
| SCHEMBL30981331 | 0.88 | ALDH1A1 (0.57) | LMNAALDH1A1MAPTGPR119ENPP2 | |
| SCHEMBL328236 | 0.86 | GPR119 (0.57) | LMNAALDH1A1MAPTGPR119ENPP2 | |
| SCHEMBL30990648 | 0.85 | ALDH1A1 (0.69) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL594206 | 0.85 | MAPT (1.00) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL5781834 | 0.84 | MAPT (0.73) | LMNAALDH1A1MAPTSMN1; SMN2ENPP2 | |
| SCHEMBL30998103 | 0.84 | MAPT (0.55) | LMNAALDH1A1MAPTENPP2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| CN-115836056-A | NOTCH inhibitors and uses thereof | STEMSYNERGY疗法有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | LMNA 926/4885ALDH1A1 932/4885MAPT 2459/4885 |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | LMNA 3567/4885ALDH1A1 2288/4885MAPT 3735/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | LMNA 3783/4885ALDH1A1 1345/4885MAPT 981/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | LMNA 4394/4885ALDH1A1 1629/4885MAPT 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.